Ling Bai

1.5k total citations
32 papers, 1.1k citations indexed

About

Ling Bai is a scholar working on Molecular Biology, Oncology and Biomaterials. According to data from OpenAlex, Ling Bai has authored 32 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 11 papers in Oncology and 11 papers in Biomaterials. Recurrent topics in Ling Bai's work include Nanoparticle-Based Drug Delivery (11 papers), Nanoplatforms for cancer theranostics (8 papers) and Cancer, Hypoxia, and Metabolism (5 papers). Ling Bai is often cited by papers focused on Nanoparticle-Based Drug Delivery (11 papers), Nanoplatforms for cancer theranostics (8 papers) and Cancer, Hypoxia, and Metabolism (5 papers). Ling Bai collaborates with scholars based in China, United States and Taiwan. Ling Bai's co-authors include Jiuwei Cui, Cheng Jin, Huimin Tian, Naifei Chen, Rilan Bai, Zheng Lv, Lingyu Li, Guozhen Guo, Hong Wu and Wenjun Wang and has published in prestigious journals such as Blood, Nature Cell Biology and Biomaterials.

In The Last Decade

Ling Bai

29 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ling Bai China	17	461	317	256	243	204	32	1.1k
Worapol Ngamcherdtrakul United States	17	560 1.2×	265 0.8×	200 0.8×	290 1.2×	372 1.8×	26	1.3k
Zeting Yuan China	18	411 0.9×	200 0.6×	135 0.5×	238 1.0×	275 1.3×	31	1.0k
Sanam Sadreddini Iran	16	734 1.6×	281 0.9×	265 1.0×	150 0.6×	138 0.7×	25	1.4k
Xiao Xu China	21	615 1.3×	222 0.7×	164 0.6×	306 1.3×	475 2.3×	56	1.3k
Hsiang‐i Tsai China	16	537 1.2×	165 0.5×	123 0.5×	191 0.8×	167 0.8×	32	964
Sufang Zhou China	20	690 1.5×	240 0.8×	285 1.1×	112 0.5×	187 0.9×	69	1.2k
Leyuan Xu United States	26	615 1.3×	156 0.5×	152 0.6×	181 0.7×	159 0.8×	36	1.4k
Yufeng Chen China	20	434 0.9×	338 1.1×	101 0.4×	155 0.6×	110 0.5×	48	1.1k
Liteng Lin China	18	368 0.8×	234 0.7×	266 1.0×	206 0.8×	268 1.3×	39	1.1k

Countries citing papers authored by Ling Bai

Since Specialization

Citations

This map shows the geographic impact of Ling Bai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ling Bai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ling Bai more than expected).

Fields of papers citing papers by Ling Bai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ling Bai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ling Bai. The network helps show where Ling Bai may publish in the future.

Co-authorship network of co-authors of Ling Bai

This figure shows the co-authorship network connecting the top 25 collaborators of Ling Bai. A scholar is included among the top collaborators of Ling Bai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ling Bai. Ling Bai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cheng, Yi, Ling Bai, & Jiuwei Cui. (2025). Harnessing multi-omics approaches to decipher tumor evolution and improve diagnosis and therapy in lung cancer. Biomarker Research. 13(1). 140–140.

Hsu, Che-Chia, Chi‐Yun Wang, Rajesh Manne, et al.. (2025). ALDH4A1 functions as an active component of the MPC complex maintaining mitochondrial pyruvate import for TCA cycle entry and tumour suppression. Nature Cell Biology. 27(5). 847–862. 2 indexed citations

Bai, Ling, et al.. (2025). Efficacy and Safety of EGF / EGFR Vaccines in EGFR ‐Driven Solid Tumors: A Systematic Review and Meta‐Analysis of Controlled and Single‐Arm Studies. Cancer Medicine. 14(19). e71295–e71295.

Penugurti, Vasudevarao, et al.. (2024). AMPK: The energy sensor at the crossroads of aging and cancer. Seminars in Cancer Biology. 106-107. 15–27. 26 indexed citations

Guo, Feifei, Yi Zhang, Ling Bai, & Jiuwei Cui. (2023). Natural killer cell therapy targeting cancer stem cells: Old wine in a new bottle. Cancer Letters. 570. 216328–216328. 15 indexed citations

Bai, Ling, Lei Zhou, Wei Han, et al.. (2023). BAX as the mediator of C-MYC sensitizes acute lymphoblastic leukemia to TLR9 agonists. Journal of Translational Medicine. 21(1). 108–108. 4 indexed citations

Bai, Rilan, Zheng Lv, Chen Xiao, et al.. (2020). Precision Detection Technology: Equipping Precision Oncology with Wings. Journal of Oncology. 2020. 1–8. 5 indexed citations

Wang, Wenjun, Ling Bai, Dongsheng Xu, Wei Li, & Jiuwei Cui. (2020). Immunotherapy: A Potential Approach to Targeting Cancer Stem Cells. Current Cancer Drug Targets. 21(2). 117–131. 5 indexed citations

Bai, Rilan, Naifei Chen, Lingyu Li, et al.. (2020). Mechanisms of Cancer Resistance to Immunotherapy. Frontiers in Oncology. 10. 1290–1290. 249 indexed citations

10.

Bai, Ling, Wenqian Li, Weijia Zheng, et al.. (2020). Promising targets based on pattern recognition receptors for cancer immunotherapy. Pharmacological Research. 159. 105017–105017. 35 indexed citations

11.

Bai, Ling, et al.. (2019). Targeting T cell metabolism in the tumor microenvironment: an anti-cancer therapeutic strategy. Journal of Experimental & Clinical Cancer Research. 38(1). 403–403. 98 indexed citations

12.

Wang, Hong, Rui Guo, Zhonghua Du, et al.. (2018). Epigenetic Targeting of Granulin in Hepatoma Cells by Synthetic CRISPR dCas9 Epi-suppressors. Molecular Therapy — Nucleic Acids. 11. 23–33. 56 indexed citations

13.

Zhao, Yuguang, Wenjing Song, Zongqiang Wang, et al.. (2017). Resveratrol attenuates testicular apoptosis in type 1 diabetic mice: Role of Akt-mediated Nrf2 activation and p62-dependent Keap1 degradation. Redox Biology. 14. 609–617. 129 indexed citations

14.

Bai, Ling, Wei Chen, Jingtao Chen, et al.. (2017). Heterogeneity of Toll-like receptor 9 signaling in B cell malignancies and its potential therapeutic application. Journal of Translational Medicine. 15(1). 51–51. 23 indexed citations

15.

Jin, Cheng, Wenqing Yang, Ling Bai, Junqing Wang, & Dou Ke-feng. (2011). Preparation and characterization of targeted DOX–PLGA–PEG micelles decorated with bivalent fragment HAb18 F(ab′) 2 for treatment of hepatocellular carcinoma. Journal of Controlled Release. 152. e14–e15. 8 indexed citations

16.

Jin, Cheng, Ling Bai, Hong Wu, et al.. (2009). Cytotoxicity of Paclitaxel Incorporated in PLGA Nanoparticles on Hypoxic Human Tumor Cells. Pharmaceutical Research. 26(7). 1776–1784. 73 indexed citations

17.

Jin, Cheng, Haimin Li, Yong He, et al.. (2009). Combination chemotherapy of doxorubicin and paclitaxel for hepatocellular carcinoma in vitro and in vivo. Journal of Cancer Research and Clinical Oncology. 136(2). 267–274. 51 indexed citations

18.

Jin, Cheng, Ling Bai, Hong Wu, et al.. (2008). Paclitaxel-loaded poly(D,L-lactide-co-glycolide) nanoparticles for radiotherapy in hypoxic human tumor cells in vitro. Cancer Biology & Therapy. 7(6). 911–916. 32 indexed citations

19.

Jin, Cheng, et al.. (2007). The effect of paclitaxel-loaded nanoparticles with radiation on hypoxic MCF-7 cells. Journal of Clinical Pharmacy and Therapeutics. 32(1). 41–47. 38 indexed citations

20.

Jin, Cheng, Ling Bai, & Guozhen Guo. (2007). Radiosensitization by the Combination of SR-2508 and Paclitaxel in Hypoxic Human Tumor Cells in vitro. Journal of Radiation Research. 48(3). 179–185. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact